Two Indian Nationals Charged with Smuggling Counterfeit Ozempic from China

Two Indian Nationals Charged in Counterfeit Ozempic Smuggling Case

In a significant federal indictment, two Indian nationals, Swapnadip Roy and Vicky Ramancha, have been charged in Florida for their alleged involvement in a scheme to smuggle counterfeit Ozempic from China. The charges come amid growing concerns over the public health risks associated with counterfeit medications, which exploit unsuspecting consumers.

Charges and Legal Proceedings

The Department of Justice (DOJ) announced that Roy, aged 33, has been extradited from Italy and appeared in U.S. District Court in Tampa on Tuesday. Both Roy and his co-accused, 37-year-old Ramancha, face multiple serious charges. These include one count of conspiracy to commit smuggling and to defraud the United States, along with three counts of smuggling and two counts of selling counterfeit drugs. If convicted, they each face a potential maximum sentence of 71 years in prison. However, Ramancha remains at large, complicating the legal proceedings further.

Allegations of Counterfeit Drug Distribution

According to court documents, the alleged activities of Roy and Ramancha began in July 2023 and extended through the following April, during which they purportedly received counterfeit versions of Ozempic from unauthorized sources in China. Ozempic, a weight-loss medication produced by Novo (formerly Novo Nordisk), has gained immense popularity but is also a target for counterfeiters. The DOJ claims that the drugs they distributed came complete with counterfeit packaging, including labels and needles, designed to deceive customers into believing they were purchasing genuine products authorized by the manufacturer.

In July 2023, Ramancha allegedly entered a sales agreement with an unidentified company located in Lakeland, Florida, wherein he committed to supplying them with Ozempic at significantly reduced prices. This was followed by another agreement in August with a Sanford, Florida company for similar products. Subsequent communications reveal alarming tactics employed by Roy. After the FDA took action against some of their counterfeit products in the U.S., Roy reportedly made threats to enforce compliance among distributors, warning one associate about the seriousness of their operations.

Impact on Public Health

As the counterfeit drug crisis continues, health officials emphasize the risks posed to the public. Assistant Attorney General A. Tysen Duva remarked on the gravity of the situation, stating, "Counterfeit prescription drugs threaten the health and safety of every American who depends on the integrity of our pharmaceutical supply. These defendants allegedly exploited people's health to pay themselves. We will keep pursuing anyone who seeks to deceive American consumers with counterfeit drugs."

The indictment surfaced during a period marked by a rise in the use of GLP-1 medications such as Ozempic, with a reported increase in adults using these drugs for weight loss purposes in recent years. According to a Gallup poll, U.S. adult usage had spiked to 11% in 2026 from 3% just two years prior, highlighting the growing demand and, concurrently, the risk associated with counterfeit versions flooding the market.